Top

Published in:

01-12-2021 | Multiple Sclerosis | Review

Multiple sclerosis therapy consensus group (MSTCG): answers to the discussion questions

Authors: Heinz Wiendl, Ralf Gold, Frauke Zipp, for the Multiple Sclerosis Therapy Consensus Group

Published in: Neurological Research and Practice | Issue 1/2021

Excerpt

An explicit goal of multiple sclerosis (MS) therapy is the “best possible disease control”, including the “best possible quality of life” of the patient, with the option to use highly effective therapeutics early or as early as possible in response to disease activity. Specifically, the appropriate disease-modifying therapy (DMT) is selected based on the individual patient, and incorporates a situation and prognostic analysis that includes disease activity, disease severity, balancing therapy safety and risks, and considering the patient’s age, gender, and living situation. From the perspective of the MSTCG (Multiple Sclerosis Therapy Consensus Group) and supported by several large observational and registry studies, modern MS therapy can and should prevent the accumulation of disability and, thus, possible neurodegeneration. …

Available only for authorised users

Chalmer, T. A., Baggesen, L. M., Nørgaard, M., Koch-Henriksen, N., Magyari, M., Sorensen, P. S., & the Danish Multiple Sclerosis Group & Danish multiple sclerosis group (2018). Early versus later treatment start in multiple sclerosis: A register-based cohort study. Eur J Neurol, 25(10), 1262–e110. https://doi.org/10.1111/ene.13692.CrossRefPubMed

He, A., Merkel, B., Brown, J. W. L., MSBase study group, et al. (2020). Timing of high-efficacy therapy for multiple sclerosis: A retrospective observational cohort study. Lancet Neurol, 19(4), 307–316.CrossRefPubMed

Kavaliunas, A., Manouchehrinia, A., Stawiarz, L., Ramanujam, R., Agholme, J., Hedström, A. K., … Hillert, J. (2017). Importance of early treatment initiation in the clinical course of multiple sclerosis. Multiple Sclerosis, 23(9), 1233–1240. https://doi.org/10.1177/1352458516675039.CrossRefPubMed

Brown, J. W. L., Coles, A., Horakova, D., Havrdova, E., Izquierdo, G., Prat, A., … for the MSBase Study Group & MSBase study group (2019). Association of Initial Disease-Modifying Therapy with Later Conversion to secondary progressive multiple sclerosis. JAMA, 321(2), 175–187. https://doi.org/10.1001/jama.2018.20588.CrossRefPubMedPubMedCentral

Gass, A., & Costello, F. E. (2018). Optic neuritis in the diagnosis of MS: More than meets the eye. Neurology, 91(12), 545–546. https://doi.org/10.1212/WNL.0000000000006189.CrossRefPubMed

Thompson, A. J., Banwell, B. L., Barkhof, F., Carroll, W. M., Coetzee, T., Comi, G., … Cohen, J. A. (2018). Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol, 17(2), 162–173. https://doi.org/10.1016/S1474-4422(17)30470-2.CrossRefPubMed

Zipp, F., Oh, J., Fragoso, Y. D., & Waubant, E. (2019 Aug). Implementing the 2017 McDonald criteria for the diagnosis of multiple sclerosis. Nature Reviews. Neurology, 15(8), 441–445. https://doi.org/10.1038/s41582-019-0194-0.CrossRefPubMed

Rae-Grant, A., Day, G. S., Marrie, R. A., et al. (2018). Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the guideline development, dissemination, and implementation Subcommittee of the American Academy of neurology. Neurology, 90(17), 777–788.CrossRefPubMed

Bittner, S., & Zipp, F. (2018). AAN unveils new guidelines for MS disease-modifying therapy. Nature Reviews. Neurology, 14(7), 384–386. https://doi.org/10.1038/s41582-018-0026-7.CrossRefPubMed

10.

Lünemann, J. D., Ruck, T., Muraro, P. A., Bar-Or, A., & Wiendl, H. (2020). Immune reconstitution therapies: Concepts for durable remission in multiple sclerosis. Nature Reviews. Neurology, 16(1), 56–62. https://doi.org/10.1038/s41582-019-0268-z.CrossRefPubMed

11.

Coles, A. J., Cohen, J. A., Fox, E. J., Giovannoni, G., Hartung, H. P., Havrdova, E., … CARE-MS II and CAMMS03409 Investigators (2017). Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings. Neurology, 89(11), 1117–1126. https://doi.org/10.1212/WNL.0000000000004354.CrossRefPubMedPubMedCentral

12.

Patti, F., Visconti, A., Capacchione, A., CLARINET-MS Study Group, et al. (2020). Long-term effectiveness in patients previously treated with cladribine tablets: a real-world analysis of the Italian multiple sclerosis registry (CLARINET-MS). Ther Adv Neurol Disord, 13, 1756286420922685.CrossRefPubMedPubMedCentral

13.

Kister, I., Spelman, T., Alroughani, R., Lechner-Scott, J., Duquette, P., Grand'Maison, F., … Butzkueven, H. (2016). Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: A propensity score-matched study. J Neurol Neurosurg Psychiatry, 87(10), 1133–1137. https://doi.org/10.1136/jnnp-2016-313760.CrossRefPubMed

14.

Wiendl, H., Calabresi, P. A., & Meuth, S. G. (2018). Defining response profiles after alemtuzumab: Rare paradoxical disease exacerbation. Neurology, 90(7), 309–311. https://doi.org/10.1212/WNL.0000000000004969.CrossRefPubMed

15.

Pfeuffer S, Ruck T, Pul R, et al. Impact of previous disease-modifying treatment on effectiveness and safety outcomes, among patients with multiple sclerosis treated with alemtuzumab. J Neurol Neurosurg Psychiatr. https://doi.org/10.1136/jnnp-2020-325304. Epub ahead of print 12 March 2021.

16.

Barry, B., Erwin, A. A., Stevens, J., & Tornatore, C. (2019). Fingolimod rebound: A review of the clinical experience and management considerations. Neurol Ther, 8(2), 241–250. https://doi.org/10.1007/s40120-019-00160-9.CrossRefPubMedPubMedCentral

17.

Prosperini, L., Kinkel, R. P., Miravalle, A. A., et al. (2019). Post-natalizumab disease reactivation in multiple sclerosis: Systematic review and meta-analysis. Ther Adv Neurol Disord, 12, 1756286419837809.CrossRefPubMedPubMedCentral

18.

Butzkueven H, Spelman T, Horakova D, et al. Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registry. Eur J Neurol. https://doi.org/10.1111/ene.14824. Epub ahead of print 16 March 2021.

19.

Montalban, X., Hauser, S. L., Kappos, L., Arnold, D. L., Bar-Or, A., Comi, G., … Wolinsky, J. S. (2017). Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med, 376(3), 209–220. https://doi.org/10.1056/NEJMoa1606468.CrossRefPubMed

20.

Bar-Or, A., Calkwood, J. C., Chognot, C., Evershed, J., Fox, E. J., Herman, A., … Traboulsee, A. (2020). Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study. Neurology, 95(14), e1999–e2008. https://doi.org/10.1212/WNL.0000000000010380.CrossRefPubMedPubMedCentral

Title: Multiple sclerosis therapy consensus group (MSTCG): answers to the discussion questions
Authors: Heinz Wiendl
Ralf Gold
Frauke Zipp
for the Multiple Sclerosis Therapy Consensus Group
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Multiple Sclerosis
Ocrelizumab
Natalizumab
Ocrelizumab
Published in: Neurological Research and Practice / Issue 1/2021
Electronic ISSN: 2524-3489
DOI: https://doi.org/10.1186/s42466-021-00140-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Multiple sclerosis therapy consensus group (MSTCG): answers to the discussion questions

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2021

Closure or medical therapy of patent foramen ovale in cryptogenic stroke: prospective case series

Neurological research and practice: the first milestone has been reached

Profiles of patients’ self-reported health after acute stroke

Simulation-based training improves patient safety climate in acute stroke care (STREAM)

Successful treatment of thromboses of major arteries after ChAdOx1 nCov-19 vaccination

COX2 expression is associated with preoperative tumor volume but not with volumetric tumor growth in vestibular schwannoma